奥齿泰(Osstem Implant)，将于明天(2月17日)接受韩国证券交易所裁定

亚洲最大的种植牙企业，韩国上市公司…

来源：The Korea Times

Fates of SillaJen, Osstem Implant to be determined this week

By Anna J. Park
The fates of two scandal-ridden companies are to be decided this week, as the Korea Exchange (KRX) is set to make its decisions on their listing status on Thursday and Friday, respectively.

First to face the KRX’s judgment will be Osstem Implant, which was suspended from stock trading at the start of the year due to an employee having embezzled over 221 billion won ($184 million). On that day, the bourse operator will decide whether to forward the case to its corporate evaluation committee for an additional, more thorough assessment of the dental implant materials company’s listing. The decision was scheduled to be completed by the end of last month, but it was delayed to this week due to the need for a cautious approach.

If the KRX decides on Thursday that Osstem Implant doesn’t need further assessment by the corporate evaluation committee, the trading suspension will be lifted on the company’s stocks and trading will resume on Friday. If the KRX decides it needs to go through the corporate evaluation committee inspection, however, the committee will decide whether to delist the company or give it a grace period, giving it a second chance to improve.

On Friday, the KRX’s Kosdaq market committee will make a significant decision regarding SillaJen: whether the biopharmaceutical company should be delisted or instead be given a grace period to improve its situation. About a month earlier, the bourse operator’s corporate evaluation committee decided to delist the bio tech company, sending a huge blow to its minor shareholders. Following the corporate evaluation committee’s delisting decision, the Kosdaq market committee has to reach its own judgment by Friday.

The Kosdaq market committee’s decision could result in one of the three outcomes: delisting, maintaining of its listing status or allowance of a grace period. If the market committee once again decides on delisting, another meeting could be held for deliberations.

SillaJen’s stocks have been suspended since May 2020, due to allegations of embezzlement and other malpractices by the firm’s former and incumbent management.

Facing an uncertain future, the two firms’ minor shareholders have been under extreme stress and anxiety. SillaJen had over 174,000 minor shareholders as of the end of 2020, while Osstem Implant had 19,857 as of last September.

以下来自谷歌翻译，不一定准确，一切以英文报道为主：

SillaJen、Osstem Implant 的命运将于本周确定

By Anna J. Park

两家丑闻缠身的公司的命运将在本周决定，因为韩国证券交易所(KRX)将分别在周四和周五就其上市状态做出决定。

首先面临 KRX 判决的是 Osstem Implant，该公司在年初因一名员工挪用了超过 2210 亿韩元(1.84亿美元)而被暂停股票交易。当天，交易所运营商将决定是否将案件提交其企业评估委员会，以对牙科植入材料公司的上市情况进行额外、更全面的评估。该决定原定于上月底完成，但由于需要谨慎行事，因此推迟到本周。

如果KRX周四决定Osstem Implant不需要企业评估委员会进一步评估，公司股票将解除停牌，周五恢复交易。但是，如果KRX决定需要通过企业评估委员会检查，委员会将决定是否将公司退市或给予宽限期，给它第二次改进的机会。

周五，KRX 的科斯达克市场委员会将对 SillaJen 做出重大决定：是否应该将这家生物制药公司退市，或者给予宽限期以改善其状况。大约一个月前，交易所运营商的企业评估委员会决定将这家生物科技公司退市，对其小股东造成巨大打击。根据企业评估委员会的退市决定，科斯达克市场委员会必须在周五之前做出自己的判断。

科斯达克市场委员会的决定可能导致以下三种结果之一：退市、维持其上市地位或给予宽限期。如果市场委员会再次决定退市，可以再次召开会议审议。

SillaJen 的股票自 2020 年 5 月以来一直被停牌，原因是该公司前任和现任管理层涉嫌贪污和其他不当行为。

面对不确定的未来，两家公司的小股东一直承受着极大的压力和焦虑。截至 2020 年底，SillaJen 拥有超过 174,000 名小股东，而截至去年 9 月，Osstem Implant 拥有 19,857 名小股东。